Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
drugs
4
×
life sciences
national blog main
new york blog main
4
×
new york top stories
akcea therapeutics
alnylam pharmaceuticals
boston top stories
clinical trials
inotersen
national top stories
patisiran
san diego blog main
san diego top stories
tafamidis
biotech
boston
fda
hereditary transthyretin amyloidosis
new york
onpattro
pfizer
regeneron pharmaceuticals
rna interference
alirocumab
amgen
anylam pharmaceuticals
barry greene
boston university
cardiomyopathy
dan ollendorf
european medicines agency
evercore isi
evolocumab
harvard pilgrim health care
heart attack
inclisiran
institute for clinical and economic review
john berk
What
alnylam
4
×
drug
fda
rna
ago
medicine
medicines
patients
uses
akcea
amyloidosis
approve
approved
approves
attr
available
awaits
based
battle
biological
cells
cholesterol
crossed
data
debilitating
decades
decision
discovered
disease
ema
employ
europe
evidence
fingers
follows
friday
gene
genetic
harmful
heart
Language
Current search:
drugs
×
alnylam
×
" new york blog main "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision